Glucagonoma Case Report and Scoping Review on Somatostatin Analogue Efficacy

25 case reports and series from a scoping review of 1,712 reviewed cases on glucagonoma and neuroendocrine tumors. The data, authored by figshare admin karger and last updated in 2026, includes patient demographics, treatment with somatostatin analogues, and clinical outcomes for necrolytic migratory erythema.

Use Cases

• Analyze the efficacy of somatostatin analogues in resolving necrolytic migratory erythema based on the reported 80% clinical improvement rate.
• Study patient demographics and survival outcomes in glucagonoma cases based on the reported 56% female patient rate and 11-month median overall survival.
• Review clinical presentation details for glucagonoma diagnosis based on described symptoms like migratory, pruritic skin lesions and elevated serum glucagon levels.

Strengths

• Includes data from a scoping review of 1,712 cases, providing a structured literature synthesis.
• Reports specific clinical metrics, including an 80% improvement rate for NME with SSAs and a mean patient age of 59.74 years.

Limitations

• The primary data format is a PDF, which likely contains unstructured text requiring manual extraction for analysis.
• Row count and column-level data are unknown, limiting suitability assessment for quantitative modeling.
• The dataset focuses on a specific, rare condition, which may limit generalizability.

Provenance

Source

figshare

Collection Method

Scoping review of case reports and series from Medline.

Freshness

Last updated 2026-05-16 09:55:08